The results of a 114-case series of patients with metastatic HNSCC treated with anti-PD-1 therapy was presented at ASCO 2018, demonstrating that patients who manifested an irAE had improved outcomes compared to those that did not. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.